



Change in Authorization Requirement for Opioid Treatment Programs for Medicare Members

Optum Behavioral Health will begin requiring authorization for Opioid Treatment Programs for Medicare Members effective February 1, 2021. These Services include:

G2067	Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)
G2068	Medication assisted treatment, buprenorphine (oral); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)
G2073	Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)
G2074	Medication assisted treatment, weekly bundle not including the drug, including substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)

Authorization will be required for members who receive services on or after **February 1, 2021**.

To obtain Authorization, call the number on the back of the Member’s ID Card. Have the following information available:

- * Member Name
- * Member DOB
- * Member ID #
- * Dates of Service to be authorized
- * Services to be authorized

A CMS OTP Medicare number will be required for reimbursement.

The following codes do not require authorization: G2076, G2077, G2078, G2079, G2080, G2215, and G2216.

If you have any questions, please contact the Optum Provider Service Line at 1-877-614-0484.